Plasma exchange in immune-mediated neuropathies

Curr Opin Neurol. 2008 Oct;21(5):547-54. doi: 10.1097/WCO.0b013e32830b0f61.

Abstract

Purpose of review: Plasma exchange is frequently used for treatment of immune-mediated neuropathies. Here, we review the current value of plasma exchange in the treatment of different forms of immune-mediated neuropathies and discuss latest developments.

Recent findings: Plasma exchange is used in various disease conditions; however, of all immune-mediated disorders of the peripheral nerve, Guillain-Barré syndrome represents the disease entity in which short and long-term efficacy, optimal frequency, side effects and cost effectiveness of plasma exchange are best documented. Although randomized trials evaluated the value of plasma exchange in chronic forms of immune-neuropathies, its long-term efficacy and its optimal frequency still remain unclear.

Summary: Especially in chronic forms of immune-mediated neuropathies, plasma exchange needs to be further evaluated in clinical trials to assess long-term efficacy and its potential as adjuvant treatment option.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Guillain-Barre Syndrome / immunology
  • Guillain-Barre Syndrome / therapy
  • Humans
  • Immunoglobulins, Intravenous / economics
  • Immunoglobulins, Intravenous / therapeutic use
  • Paraproteinemias / immunology
  • Paraproteinemias / pathology
  • Paraproteinemias / therapy
  • Peripheral Nervous System Diseases* / immunology
  • Peripheral Nervous System Diseases* / therapy
  • Plasma Exchange* / economics
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / immunology
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / therapy
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous